1·This information is in the Boxed Warning of the sirolimus label.
这一点在西罗莫司标签的黑框警告中有提示。
2·The FDA is determining whether a labeling change for sirolimus is needed.
FDA正在酝酿是否需要修改西罗莫司的标签信息。
3·Therapeutic drug monitoring should not be the sole basis for adjusting sirolimus therapy.
治疗药物监测不应作为调整西罗莫司治疗的唯一根据。
4·Proteinuria was associated with the presence of graft glomerular pathology and the use of sirolimus.
蛋白尿症与肾小球的病变以及西罗莫司(免疫抑制剂)的使用相关。
5·Patients unable to take the tablets should be prescribed the sirolimus oral solution and instructed in its use.
不能口服片剂的患者应给予西罗莫司口服液，并指导给药。
6·Kushwaha and colleagues tested the use of sirolimus as an alternative anti-proliferative immunosuppressant drug.
Kushwaha和他的同事试验西罗莫司作为可选择的抗增值免疫抑制药物的使用。
7·Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving kidney transplants.
西罗莫司用于在13岁及以上接受肾移植患者中预防器官排斥反应。
8·The safety and the efficacy of sirolimus as an immunosuppressant have not been established in liver or lung transplant patients.
该药作为一种免疫抑制剂在肝或肺移植患者中的安全性和有效性尚未得到确认。
9·In all, 12 patients were neutropenic (
共12例基线时有粒细胞缺乏（<500/微升），10例接受了类固醇激素治疗，16例接受了钙调磷酸酶抑制剂或西罗莫斯治疗。
10·Drug discontinuation due to an adverse event was also more frequent in the sirolimus cohort compared to those patients continued on CNI.
在西罗莫司组中因不良事件而导致停药的也多于继续使用CNI治疗的患者。